PURPLE BIOTECH LTD-ADR (PPBT)
US74638P1093 - ADR
PURPLE BIOTECH LTD-ADR
NASDAQ:PPBT (5/3/2024, 7:13:05 PM)
After market: 0.57 +0.04 (+7.55%)0.53
-0.01 (-2.03%)
Company Profile
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Company Info
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104
P: 97239333121
CEO: Gil Efron
Employees: 13
Website: https://purple-biotech.com/
PPBT News
9 days ago - Purple Biotech Ltd. Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingInterim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT,...
a month ago - Purple Biotech Ltd. Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 20242 months ago - Purple Biotech Ltd. Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyContribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity...
2 months ago - InvestorPlacePPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023PPBT stock results show that Purple Biotech met analyst estimates for earnings per share the fourth quarter of 2023.
PPBT Twits
Here you can normally see the latest stock twits on PPBT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
